NCT02975479View on ClinicalTrials.gov

Intralymphatic Immunotherapy in Increasing Doses, Substudy

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

May 31, 2016

Primary Completion Date

June 20, 2022

Study Completion Date

June 20, 2022

Conditions
Rhinitis, Allergic, Seasonal
Interventions
DRUG

ALK Diluent

DRUG

ALK Alutard SQ 5-grasses or ALK Alutard Birch

Depot formulation of relevant allergen adsorbed to aluminium hydroxide in a suspension.

Trial Locations (2)

221 85

Allergic Unit at the Department of Oto-Rhino-Laryngology at Skåne University Hospital Lund, Lund

141 86

ENT-department, Karolinska University Hospital Huddinge (ENT-department B51), Stockholm

All Listed Sponsors
collaborator

Skane University Hospital

OTHER

collaborator

Karolinska University Hospital

OTHER

lead

Karolinska Institutet

OTHER

NCT02975479 - Intralymphatic Immunotherapy in Increasing Doses, Substudy | Biotech Hunter | Biotech Hunter